A SHOT AT IMMUNITY
The last time Pranav Sharma (name changed on request) was at AIIMS, Delhi, it was for the birth of his best friend’s son. The 33-year-old, however, returned to the institute on July 20 as one of 1,124 individuals being screened for a Covid vaccine trial, and who will receive a dose of the indigenously developed Covaxin as part of the ongoing Phase 1 and 2 of the trial. “It is for the greater good of our planet,” he says.
Not all of the 375 people to be.
